APA (7th ed.) Citation

Takizawa, D., Arai, H., Shibasaki, M., Tamura, Y., Kakizaki, S., Hatanaka, T., . . . Uraoka, T. (2026). Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology, 31(3), 159. https://doi.org/10.3390/curroncol33030159

Chicago Style (17th ed.) Citation

Takizawa, Daichi, et al. "Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma." Current Oncology 31, no. 3 (2026): 159. https://doi.org/10.3390/curroncol33030159.

MLA (9th ed.) Citation

Takizawa, Daichi, et al. "Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma." Current Oncology, vol. 31, no. 3, 2026, p. 159, https://doi.org/10.3390/curroncol33030159.